Rank #1830BCYC

Bicycle Therapeutics plc

$5.54

2.97% (Daily)

Market Cap

$384.30M

Revenue

$28.34M

Rank by MCap

#1830

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Kevin Lee M.B.A., Ph.D.

Headquarters

Cambridge

Employees

305

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressin...